英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
Mosaical查看　Mosaical　在百度字典中的解释百度英翻中〔查看〕
Mosaical查看　Mosaical　在Google字典中的解释Google英翻中〔查看〕
Mosaical查看　Mosaical　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Revolade™ (eltrombopag olamine) | Home
    REVOLADE® (eltrombopag) is the thrombopoietin receptor agonist (TPO-RA) proven in the most disease states: adult and paediatric chronic immune thrombocytopenia (ITP), adult and paediatric severe aplastic anaemia (SAA), and chronic hepatitis C virus–associated thrombocytopenia (HCVaT)
  • Revolade™ (eltrombopag olamine) | Dosing and administration
    REVOLADE® (eltrombopag) offers the convenience of once-daily oral dosing in immune thrombocytopenia (ITP), severe aplastic anaemia (SAA), and chronic hepatitis C virus–associated thrombocytopenia (HCVaT)
  • Revolade™ (eltrombopag olamine) | Patient experience: why choose REVOLADE
    REVOLADE® (eltrombopag) offers patients with chronic immune thrombocytopenia (ITP) effective therapy that helps to overcome some of the concerns they may have with other therapies such as corticosteroids, rituximab, splenectomy, and other thrombopoietin receptor agonists (TPO-RAs)
  • Revolade™ (eltrombopag olamine) | Efficacy: ITP
    REVOLADE® (eltrombopag) is the thrombopoietin receptor agonist (TPORA) that offers a proven and trusted response, including sustained response, in patients with chronic immune thrombocytopenia (ITP)
  • Revolade™ (eltrombopag olamine) | Efficacy: Study designs
    REVOLADE® (eltrombopag) has been proven in numerous clinical studies in adult and paediatric chronic immune thrombocytopenia (ITP), adult and paediatric severe aplastic anaemia (SAA), and chronic hepatitis C virus–associated thrombocytopenia (HCVaT)
  • Revolade™ (eltrombopag olamine) | Safety information
    REVOLADE® (eltrombopag) safety information for the treatment of adult and paediatric patients with immune thrombocytopenia (ITP), adult and paediatric patients with severe aplastic anaemia (SAA), and adult patients with chronic hepatitis C virus–associated thrombocytopenia (HCVaT)
  • Revolade™ (eltrombopag olamine) | Efficacy: SAA
    REVOLADE® (eltrombopag), a thrombopoietin receptor agonist (TPO-RA), enables many patients with relapsed refractory severe aplastic anaemia (SAA) to achieve a multilineage response and remain transfusion-free
  • Revolade, INN-eltrombopag
    Revolade is indicated in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4 4 and 5 1)
  • Revolade™ (eltrombopag olamine) | MOA
    REVOLADE® (eltrombopag) has a unique mechanism of action (MOA) that complements, rather than competes with endogenous thrombopoietin, stimulating an immunomodulatory response to promote platelet production in immune thrombocytopenia (ITP) and deliver a trilineage response in severe aplastic anaemia (SAA)
  • Revolade™ (eltrombopag olamine) | Safety: ITP
    REVOLADE® (eltrombopag) has a proven, well-established safety profile in adult and paediatric patients with chronic immune thrombocytopenia (ITP), with rate of venous thromboembolism in the expected range for patients with ITP, and does not induce bone marrow fibrosis





中文字典-英文字典  2005-2009